|
|
We are delighted to invite you to register for the online experience of ARiA XI, taking place March 6–7, 2026. Whether you plan on joining from the comfort of your home or workplace, ARiA XI offers an excellent online platform designed to deliver the engaging and comprehensive educational program seamlessly to you. |
|
|
|
Registration for virtual delegates is now open, and we encourage you to register today: |
|
|
|
ARiA has helped foster a community of healthcare professionals and scientists united by one common goal: to advance early suspicion and diagnosis of ATTR-CM, enabling patients to benefit from timely and holistic disease management. We welcome you to be a part of this community and gain insights from the knowledge and experience shared by leading international expert faculty members. Thank you in advance for your time, and we look forward to seeing you at
ARiA XI! |
|
|
|
| Friday, March 6, 2026 | 08:45–10:45 CET; 13:45–15:25 CET; 17:15–17:30 CET |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ARiA XI: celebrating the 11th ARiA |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
Identifying the patient with ATTR-CM: supporting early diagnosis |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ATTR-CM from bench to bedside |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
From biology to disease: understanding the role of the TTR protein |
|
|
| |
|
|
|
|
|
|
|
|
|
|
| Recognizing wild-type and variant ATTR-CM for earlier diagnosis |
|
|
| |
|
|
|
|
|
|
|
|
|
|
| Navigating the non-invasive diagnostic pathway for timely therapy initiation in ATTR-CM |
|
|
| |
|
|
|
|
|
|
|
|
|
|
| | All, moderated by
Stefano Perlini |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Initiating disease-modifying therapy in ATTR-CM: an evidence-based approach |
|
| |
|
|
|
|
|
|
|
|
|
|
|
Exploring the ATTR-CM
treatment landscape |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
Meet-the-expert session: Dispelling myths related to TTR stabilization |
|
|
| Jeffery Kelly, Mathew Maurer & Lorena Saelices |
|
|
|
|
|
|
|
|
|
|
|
|
|
| | Jeffery Kelly, Mathew Maurer & Lorena Saelices, moderated by Giovanni Palladini |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical decision-making: survival, quality of life, and safety |
|
|
|
Stefano Perlini &
Marianna Fontana |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Stefano Perlini
Marianna Fontana
& Mathew Maurer, moderated by Giovanni Palladini |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Day 1 wrap-up: what have we learned, and what is next? |
|
| |
|
|
|
|
|
|
|
|
|
|
|
Putting the patient at the heart of care |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Saturday, March 7, 2026 | 09:00–09:55 CET; 11:45–13:00 CET |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Welcome and introduction to Day 2 |
|
|
| |
|
|
|
|
|
|
|
|
|
|
Holistic management of ATTR-CM: heart failure and beyond |
|
| |
|
|
|
|
|
|
|
|
|
|
|
Why is disease monitoring important? |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
Disease progression consensus updates and practical guidance |
|
|
|
Mathew Maurer & Giovanni Palladini |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Holistic management of patients with ATTR-CM: heart failure and comorbidities |
|
|
| |
|
|
|
|
|
|
|
|
|
|
| |
All, moderated by Mathew Maurer |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The future of ATTR-CM: looking to 2026 and forward |
|
| |
|
|
|
|
|
|
|
|
|
|
|
What does success look like in ATTR-CM care? |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
What does success look like for us? |
|
|
| |
|
|
|
|
|
|
|
|
|
|
| |
All, moderated by Mathew Maurer |
|
|
|
|
|
|
|
|
|
|
|
|
|
| | Mathew Maurer
Giovanni Palladini |
|
|
|
|
|
|
|
|
|
|
|
|
|
ATTR-CM, transthyretin amyloid cardiomyopathy; Q&A, question and answer; TTR, transthyretin. |
|
|
